to persons severely affected, development of an effective vaccine is urgently needed to prevent disease. Until a vaccine becomes available, public health authorities will need to maintain their focus on surveillance, disease recognition, implementation of control measures, and public education about protective measures.

Acknowledgments

We thank Jim Schuermann, Nate Wolfe, and Alexandra Inghber for their assistance with data collection and preparation of this manuscript.

This project was generously supported in part by the Gillson Longenbaugh Foundation and the National Institutes of Health, National Institute of Allergy and Infectious Diseases (5R01AI091816-01).

Dr Murray is the associate vice-chair for research and associate professor of pediatrics in the Department of Pediatrics and National School of Tropical Medicine at Baylor College of Medicine and Texas Children’s Hospital. Her research focuses on vector-borne and zoonotic diseases.

References


Address for correspondence: Kristy O. Murray, Department of Pediatrics, National School of Tropical Medicine, 1102 Bates St, Suite 550, Houston, TX 77030, USA; email: kmurray@bcm.edu

Diphtheria

[dif-thēr′ı-ə]

F rom the Greek diphthera (leather), diphtheria is named for the tough pseudomembrane that forms in the patient’s throat. One of the earliest accounts of what may have been symptoms of diphtheria is found in Hippocrates work Epidemics III, written 2,500 years ago. Reports of epidemics of “throat distemper” began to appear in the 1500s, but before the 19th century, diphtheria was known around the world by many different names, such as Syrian ulcer, membranous angina, malignant croup, and Boulogne sore throat. In 1821, French physician Pierre Bretonneau described diphtheria’s unique clinical characteristics during an epidemic in southern France, when he named it diphtérite after the leathery texture of the pseudomembrane.

Sources


Address for correspondence: Ronnie Henry, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E03, Atlanta, GA 30333, USA; email: boq3@cdc.gov

DOI: http://dx.doi.org/10.3201/eid1911.ET1911